Amyotrophic Lateral Sclerosis Treatment Advances: Tofersen’s Impact on Survival and Quality of Life
Key TakeawaysThe G-BA's assessment of Tofersen highlights significant survival and quality of life improvements for amyotrophic lateral sclerosis patients with SOD1 mutations, particularly...
Lupus: UCB and Biogen Announce Positive Results for Dapirolizumab Pegol in SLE
Key TakeawaysDapirolizumab pegol demonstrated clinical improvement in moderate-to-severe SLE patients.
The drug also showed positive outcomes in reducing disease activity and flares.
No...
Biosimilar OPUVIZ™ Receives Positive CHMP Opinion for Aflibercept-Based Treatment in Ophthalmology
Key TakeawaysOPUVIZ™, a biosimilar referencing aflibercept (Eylea), has received a positive recommendation from the EMA's CHMP for the treatment of several retinal disorders.
...
Key TakeawaysBiogen's Phase 2/3 DEVOTE study demonstrated that a higher dose regimen of nusinersen significantly improves motor function in infants with spinal muscular...
Alzheimer’s Treatment Leqembi® (Lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
Alzheimer’s disease (AD) has taken another significant step forward in treatment, with the authorization of Leqembi® (lecanemab) in Great Britain for the treatment of...
Alzheimer’s Disease: LEQEMBI® (Lecanemab) Approved for Treatment in the United Arab Emirates
Alzheimer’s disease, a leading cause of dementia, has received a new treatment option in the United Arab Emirates (UAE) with the approval of LEQEMBI®...
Alzheimer’s collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brain. These tools have the potential...
Alzheimer’s Collaboration to Develop Blood-Based Biomarkers for Tau Pathology in Alzheimer’s Disease
Alzheimer’s Collaboration to Develop Blood-Based Biomarkers and Tests for Tau Pathology aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau...
CHMP Approves New Medicines and Biosimilars, Rejects Eisai and Biogen’s Alzheimer’s Drug
Despite the typical summer slowdown, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has shown no signs of reducing...
Eisai and Biogen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative...
